Regulation of RUNX1/AML1 during the G2/M transition

Leukemia Research

Volumn 31, Issue 6, 2007, Pages 839-851

  Wang, Suiquan ^a   Zhang, Youhong ^a   Soosairajah, Juliana ^a   Kraft, Andrew S ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cdc20; CDK1; Cell cycle; Degradation; Phosphorylation; RUNX1 AML1

Indexed keywords

AMSACRINE; APHIDICOLIN; CAMPTOTHECIN; CELL CYCLE PROTEIN 20; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE 1; GLUTATHIONE TRANSFERASE; HYBRID PROTEIN; NOCODAZOLE; PHORBOL 13 ACETATE 12 MYRISTATE; PLASMID DNA; PURVALANOL A; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO ACID SEQUENCE; ARTICLE; CELL CYCLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; FLOW CYTOMETRY; HEMATOPOIESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PURIFICATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELL DIVISION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; EMBRYONIC STEM CELLS; G2 PHASE; HEMATOPOIETIC STEM CELLS; HUMANS; JURKAT CELLS; NOCODAZOLE; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; UBIQUITIN-PROTEIN LIGASES;

EID: 34249778361     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.08.016     Document Type: Article

References (65)

1. Ducy P., Zhang R., Geoffroy V., Ridall A.L., and Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89 5 (1997) 747-754
2. Inoue K., Ozaki S., Shiga T., Ito K., Masuda T., Okado N., et al. Runx3 controls the axonal projection of proprioceptive dorsal root ganglion neurons. Nat Neurosci 5 10 (2002) 946-954
3. Ichikawa M., Asai T., Saito T., Seo S., Yamazaki I., Yamagata T., et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 10 3 (2004) 299-304
4. Kalev-Zylinska M.L., Horsfield J.A., Flores M.V., Postlethwait J.H., Vitas M.R., Baas A.M., et al. Runx1 is required for zebrafish blood and vessel development and expression of a human RUNX1-CBF2T1 transgene advances a model for studies of leukemogenesis. Development 129 8 (2002) 2015-2030
5. Growney J.D., Shigematsu H., Li Z., Lee B.H., Adelsperger J., Rowan R., et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood 106 2 (2005) 494-504
6. Okuda T., Van Deursen J., Hiebert S.W., Grosveld G., and Downing J.R. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hemtopoiesis. Cell 84 2 (1996) 321-330
7. Wang Q., Stacy T., Binder M., Marin-Padilla M., Sharpe A.H., and Speck N.A. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci USA 93 8 (1996) 3444-3449
8. Halle J.P., Hsus-Seuffert P., Woltering C., Stelzer G., and Meisterernst M. A conserved tissue-specific structure at a human T-cell receptor beta-chain core promoter. Mol Cell Biol 17 8 (1997) 4220-4229
9. Liu H., Holm M., Xie X.Q., Wolf-Watz M., and Grundstrom T. AML1/Runx1 recruits calcineurin to regulate granulocyte macrophage colony-stimulating factor by Ets1 activation. J Biol Chem 279 28 (2004) 29398-29408
10. Austin G.E., Zhao W.G., Regmi A., Lu J.P., and Braun J. Identification an upstream enhancer containing an AML1 site in the human myeloperoxidase (MPO) gene. Leuk Res 22 11 (1998) 1037-1048
11. Zhang D.E., Hetherington C.J., Meyers S., Rhoades K.L., Larson C.J., Chen H.M., et al. CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol Cell Biol 16 3 (1996) 1231-1240
12. Li X., Vradii D., Gutierrez S., Lian J.B., van Wijnen A.J., Stein J.L., et al. Subnuclear targeting of Runx1 is required for synergistic activation of the myeloid specific MCSF receptor promoter by PU.1. J Cell Biochem 96 4 (2005) 795-809
13. Lutterbach B., Westendorf J.J., Linggi B., Isaac S., Seto E., and Hiebert S.W. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J Biol Chem 275 1 (2000) 651-656
14. Miyoshi H., Kozu T., Shimizu K., Enomoto K., Maseki N., Kaneko Y., et al. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J 12 7 (1993) 2715-2721
15. Nucifora G., Birn D.J., Espinosa R.I., Erickson P., LeBeau M.M., Roulston D., et al. Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis. Blood 81 10 (1993) 2728-2734
16. Golub T.R., Barker G.F., Bohlander S.K., Hiebert S.W., Ward D.C., Bray-Ward P., et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA 92 11 (1995) 4917-4921
17. Hiebert S.W., Sun W., Davis J.N., Golub T., Shurtleff S., Buijs A., et al. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol Cell Biol 16 4 (1996) 1349-1355
18. Fischer M., Schwieger M., Horn S., Niebuhr B., Ford A., Roscher S., et al. Defining the oncogenic function of the TEL/AML1 (ETV6/RUNX1) fusion protein in a mouse model. Oncogene 24 51 (2005) 7579-7591
19. Nimer S.D., and Moore M.A. Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells. Oncogene 23 24 (2004) 4249-4254
20. Tonks A., Tonks A.J., Pearn L., Pearce L., Hoy T., Couzens S., et al. Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal. Leukemia 18 7 (2004) 1238-1245
21. Osato M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene 23 24 (2004) 4284-4296
22. Roumier C., Fenaux P., Lafage M., Imbert M., Eclache V., and Preudhomme C. New mechanisms of AML1 gene alteration in hematological malignancies. Leukemia 17 1 (2003) 9-16
23. Kurokawa M., Tanaka T., Tanaka K., Ogawa S., Mitani K., Yazaki Y., et al. Overexpression of the AML1 protooncoprotein in NIH3Ts cells leads to neoplastic transformation depending on the DNA-binding and transactivation potencies. Oncogene 12 4 (1996) 883-892
24. Wotton S.F., Blyth K., Kilbey A., Jenkins A., Terry A., Bernardin-Fried F., et al. RUNX1 transformation of primary embryonic fibroblasts is revealed in the absence of p53. Oncogene 23 32 (2004) 5476-5486
25. Bernardin-Fried F., Kummalue T., Leijen S., Collector M.I., Ravid K., and Friedman A.D. AML1/RUNX1 increase during G1 to S cell cycle progression independent of cytokine-dependent phosphorylation and induces cyclin D3 gene expression. J Biol Chem 279 15 (2004) 15678-15687
26. Peterson L.F., Boyapati A., Ranganathan V., Iwama A., Tenen D.G., Tsai S., et al. The hematopoietic transcription factor AML1 (RUNX1) is negatively regulated by the cell cycle protein cyclin D3. Mol Cell Biol 25 23 (2005) 10205-10219
27. Strom D.K., Nip J., Westendorf J.J., Linggi B., Lutterbach B., Downing J.R., et al. Expression of the AML-1 oncogene shortens the G1 phase of the cell cycle. J Biol Chem 275 5 (2000) 3438-3445
28. Bernardin F., and Friedman A.D. AML1 stimulates G1 to S progression via its transactivation domain. Oncogene 21 20 (2002) 3247-3252
29. Lou J., Cao W., Bernardin F., Ayyanathan K., Rauscher III F.J., and Friedman A.D. Exogenous cdk4 overcomes reduced cdk4 RNA and inhibition of G1 progression in hematopoietic cells expressing a dominant-negative CBF-a model for overcoming inhibition of proliferation by CBF oncoproteins. Oncogene 19 22 (2000) 2695-2703
30. Bernardin F., Yang Y., Civin C.I., and Friedman A.D. c-Myc overcomes cell cycle inhibition by CBFbeta-SMMHC, a myeloid leukemia oncoprotein. Cancer Biol Ther 1 5 (2002) 492-496
31. Kummalue T., Lou J., and Friedman A.D. Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein. Mol Cell Biol 22 23 (2002) 8278-8291
32. Burel S.A., Harakawa N., Zhou L., Pabst T., Tenen D.G., and Zhang D.E. Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol Cell Biol 21 16 (2001) 5577-5590
33. Amann J.M., Nip J., Strom D.K., Lutterbach B., Harada H., Lenny N., et al. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol 21 19 (2001) 6470-6483
34. Tanaka T., Kurokawa M., Ueki K., Tanaka K., Imai Y., Mitani K., et al. The extracellular signal-regulated kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability. Mol Cell Biol 16 7 (1996) 3967-3979
35. Zhang Y., Biggs J., and Kraft A.S. Phorbol ester treatment of K562 cells regulates the transcriptional activity of AML1c through phosphorylation. J Biol Chem 279 51 (2004) 53116-53125
36. Yamaguchi Y., Kurokawa M., Imai Y., Izutsu K., Asai T., Ichikawa M., et al. AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues. J Biol Chem 279 15 (2004) 15630-15638
37. Huang G., Shigesada K., Ito K., Wee H., Yokomizo T., and Ito Y. Dimerization with PEBP2β protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation. EMBO J 20 4 (2001) 723-733
38. Biggs J.R., Zhang Y., Peterson L.F., Garcia M., Zhang D.E., and Kraft A.S. Phosphorylation of AML1/RUNX1 regulates its degradation and nuclear matrix association. Mol Cancer Res 3 7 (2005) 391-401
39. Imai Y., Kurokawa M., Yamaguchi Y., Izutsu K., Nitta E., Mitani K., et al. The corepressor mSin3A regulates phosphorylation-induced activation, intranuclear location, and stability of AML1. Mol Cell Biol 24 3 (2004) 1033-1043
40. Peters J.M. The anaphase-promoting complex: proteolysis in mitosis and beyond. Mol Cell 9 5 (2002) 931-943
41. Castro A., Bernis C., Vigneron S., Labbe J.-C., and Lorca T. The anaphase-promoting complex: a key factor in the regulation of cell cycle. Oncogene 24 3 (2005) 314-325
42. Wasch R., and Engelbert D. Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells. Oncogene 24 1 (2005) 1-10
43. Rape M., Reddy S.K., and Kirschner M.W. The processivity of multiubiquitination by the APC determines the order of substrate degradation. Cell 124 1 (2006) 89-103
44. Stewart S., and Fang G. Destruction box-dependent degradation of Aurora B is mediated by the anaphase-promoting complex/cyclosome and cdh1. Cancer Res 65 19 (2005) 8730-8735
45. Castro A., Arlot-Bonnemains Y., Vigneron S., Labbe J.C., Prigent C., and Lorca T. APC/Fizzy-related targets Aurora-A kinase for proteolysis. EMBO Rep 3 5 (2002) 457-462
46. Hames R.S., Wattam S., Yamano H., Bacchieri R., and Fry A.M. APC/C-mediated destruction of the centrosomal kinase Nek2A occurs in early mitosis and depends upon a cyclin A-type D-box. EMBO J 20 24 (2001) 7117-7127
47. Zhao W.M., and Fang G. Anillin is a substrate of anaphase-promoting complex/cyclosome (APC/C) that controls spatial contractility of myosin during late cytokinesis. J Biol Chem 280 39 (2005) 33516-33524
48. Stewart S., and Fang G. Anaphase-promoting complex/cyclosome controls the stability of TPX2 during mitotic exit. Mol Cell Biol 25 23 (2005) 10516-10527
49. Jeung H.C., Che X.F., Haraguchi M., Furukawa T., Zheng C.L., Sumizawa T., et al. Thymidine phosphorylase suppresses apoptosis induced by microtubule-interfering agents. Biochem Pharmacol 70 1 (2005) 13-21
50. Villerbu N., Gaben A.M., Redeuilh G., and Mester J. Cellular effects of purvalanol A: a specific inhibitor of cyclin-dependent kinase activities. Int J Cancer 97 6 (2002) 761-769
51. O'Connor D.S., Wall N.R., Porter A.C., and Altieri D.C. A p34 (cdc2) survival checkpoint in cancer. Cancer Cell 2 1 (2002) 43-54
52. Qiao M., Shapiro P., Fosbrink M., Rus H., Kumar R., and Passaniti A. Cell cycle-dependent phosphorylation of the RUNX2 transcription factor by Cdc2 regulates endothelial cell proliferation. J Biol Chem 281 11 (2006) 7118-7128
53. Alappat E.C., Feig C., Boyerinas B., Volkland J., Samuels M., Murmann A.E., et al. Phosphorylation of FADD at serine 194 by CK1α regulates its nonapoptotic activities. Mol Cell Biol 19 3 (2005) 321-332
54. Knippschild U., Gocht A., Wolff S., Huber N., Lohler J., and Stoter M. The casein kinase 1 family: participation in multiple cellular processes in eukaryotes. Cellular Signaling 17 6 (2005) 675-689
55. Tseng C.J., Wang Y.J., Liang Y.C., Jeng J.H., Lee W.S., Lin J.K., et al. Microtubule damaging agents induce apoptosis in HL 60 cells and G2/M cell cycle arrest in HT 29 cells. Toxicology 175 1-3 (2002) 123-142
56. Wee H.J., Huang G., Shigesada K., and Ito Y. Serine phosphorylation of RUNX2 with novel potential functions as negative regulatory mechanisms. EMBO Rep 3 10 (2002) 967-974
57. Levanon D., Goldstein R.E., Bernstein Y., Tang H., Goldenberg D., Stifani S., et al. Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors. Proc Natl Acad Sci USA 95 20 (1998) 11590-11595
58. Littlepage L.E., and Ruderman J.V. Identification of a new APC/C recognition domain, the A box, which is required for the Cdh1-dependent destruction of the kinase Aurora-A during mitotic exit. Genes Dev 16 17 (2002) 2274-2285
59. Von der Lehr N., Johansson S., Wu S., Bahram F., Castell A., Cetinkaya C., et al. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell 11 5 (2003) 1189-1200
60. Kim S.Y., Herbst A., Tworkowski K.A., Salghetti S.E., and Tansey W.P. Skp2 regulates Myc protein stability and activity. Mol Cell 11 5 (2003) 1177-1188
61. Ang X.L., and Harper J.W. SCF-mediated protein degradation and cell cycle control. Oncogene 24 17 (2005) 2860-2870
62. Vodermaier H.C. APC/C and SCF: controlling each other and cell cycle. Curr Biol 14 18 (2004) R787-R796
63. Yamano H., Kitamura K., Kominami K., Lehmann A., Katayama S., Hunt T., et al. The spike of S phase cyclin Cig2 expression at the G1-S border in fission yeast requires both APC and SCF ubiquitin ligases. Mol Cell 6 6 (2000) 1377-1387
64. Donzelli M., Squatrito M., Ganoth D., Hershko A., Pagano M., and Draetta G.F. Dual mode of degradation of Cdc25 A phosphatase. EMBO J 21 18 (2002) 4875-4884
65. Rhoades K.L., Hetherington C.J., Rowley J.D., Hiebert S.W., Nucifora G., Tenen D.G., et al. Synergistic up-regulation of the myeloid-specific promoter of the macrophage colony-stimulating factor receptor by AML1 and the t(8:21) fusion protein may contribute to leukemogenesis. Proc Natl Acad Sci USA 93 21 (1996) 11895-11900